Drug Targets: Nuclear Receptors Flashcards

1
Q

Nuclear receptors found where?

A

In the cytoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anything that binds to nuclear receptor must be lipid soluble. Why?

A

It has to cross the membrane and get into the cytoplasm before it can interact with the receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Role of n-terminal variable domain

A

Regulate transcriptional activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Role of dna-binding domain (DBD)

A

Highly conserved; binds receptor to hormone response element in DNA by two zinc-containing regions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Role of hinge region

A

Enables intracellular translocation to the nucleus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Role of ligand-binding domain(LBD)

A

Moderately conserved; enables specific ligand binding; contains nuclear localisation sequence (NLS); also binds chaperone proteins and facilitates receptor dimerisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

AF1 role

A

Can promote the binding of other cofactors to the genetic material to influence the effects of the ligand receptor complex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

AF2 role

A

May/may not be present
-Similar to AF1 - serves to promote binding of activating factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Endogenous ligand

A

A naturally occurring small molecule that elicits a conformational change in the nuclear receptor upon binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

4 classes of nuclear receptors

A

2 major classes and 2 minor classes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Without hinge region what happens?

A

No translocation = no receptor action
Hinge region promotes dimerisation of nuclear receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What type of ligand binding are type 1 receptors? Location?

A

Homodimers
Location -cytosolic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What type of ligand binding are type 2 receptors? Location?

A

Heterodimers often with RXR
Location- nuclear

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Endogenous ligand for oestrogen receptor?

A

Sex hormone oestrogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mechanism of action for oestrogen

A
  • Bind to its receptor (oestrogen) in the cytoplasm
  • in cytoplasm you get dimerisation and couple of activation factors
  • receptor and ligand complex move to the nucleus where it will bind to destrogen response element on the DNA
  • activation factors stimulate the action of the co-activators= form linkage of receptor with RNA polymerase (role-regulate transcription of genetic material)
  • get significant effects upon cellular function
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Overactivity of the oestrogen receptor in breast tissue can lead to?
example of drug treatment

A

Forms of breast cancer
Drug-tamoxifen, fulvestrant

17
Q

Tamoxifen leads to? Fully activated transcription or partially activated transcription or no transcription

A

Partially activated transcription

18
Q

Fulvestrant leads to? Fully activated transcription or partially activated transcription or no transcription

A

No transcription

19
Q

Oestradiol leads to? Fully activated transcription or partially activated transcription or no transcription

A

Fully activated transcription

20
Q

Mechanism of action for tamoxifen

A
  • Binds to oestrogen receptor and will act to modulate the function of the receptor (still get dimerisation and translocation in nucleus)
    -Activation factor = only one activation factor, before had couple of coactivators (AF1 active, AF2 inactive)
    -Results in partially activated transcription
21
Q

Why is tamoxifen described as a partial antagonist?

A

Results in partially activated transcription as there is only one activation factor recruiting activators involved

22
Q

Mechanism of action for fulvestrant

A

-Accelerated receptor degradation as a consequence of binding
- inactivation AF1 and 2 leads to reduced nuclear localisation of the inactive oestrogen receptor
Still get nuclear translocation but no activation factors involved = no transcription

23
Q

Synthetic glucocorticoids can be used as?

A

Anti-inflammatory and immunosuppressive compounds

24
Q

Prednisolone is what type of glucocorticoid ?

A

Synthetic, anti-inflammatory and immunosuppressant effects

25
Nuclear factor kappa B
Receptor believed to be important in inflammatory signaling
26
Mechanism of action for prednisolone
- With help of a glucose response element, it bind to DNA -Once it binds to its receptor, responsible for inhibiting another receptor, nuclear factor kappa B -Moves into the nucleus and the effect of the glucocorticoid is to inhibit the function of the receptor
27
Vamorolone is currently in trials for?
Muscular dystrophy where anti-inflammatory component is more important than immunosuppressive effect
28
Pioglitazone is used in treatment for?
Diabetes
29
pioglitazone : is receptor has number of different effect such as?
- Effect in cytoplasm interfering with second messenger systems - also translocations in the nucleus where it car be heterodimerised with retinoid receptor
30
Mechanism of action for pioglitazone
Binds to peroxisome proliferator activated receptor y (PPARy) Alters transcription of genes influencing carbohydrate and lipid metabolism -Activation of PPARy increases transcription of insulin - responsive genes
31
Finerenore in clinical trials for?
Kidney disease and heart failure
32
Aldosterone is important in terms of?
Regulation of water balance and in pathological conditions, the hormone aldosterone via activation of mineralocorticoid receptors (MR), can result in fibrosis (thickening/scarring of tissue)
33
Role of finerenone
To try and reduce the effects of aldosterone by blocking it with finerenone , reducing the incidence of fibrosis
34
Rosiglitazone: despite being approved by regulators, there is issues regarding?
Its cardiovascular safety